NCT07176338Active, not recruiting
Role of Metformin in Posterior Capsule Opacification
Lens Epithelial Cell Proliferation in Patients Suffering From Diabetes and Treated With Metformin in Vitro: a Pilot Study
Source: ClinicalTrials.gov · Last updated 16 Sept 2025
Brief summary (registry, in English)
Determination of concentrations of systemically applied metformin in human lens capsule and its ability to lower the proliferation rate of human lens epithelial cells in vitro.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 8 Sept 2025
- Start date
- 12 Oct 2022
- Primary completion date
- 1 Oct 2025
- Lead sponsor
- Vienna Institute for Research in Ocular Surgery
- Diseases
- Type 2 diabetes
- NCT number
- NCT07176338
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 12 Oct 2022 to the primary completion date, 1 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous ocular surgery or trauma regarding cataract surgery
- Previous vitrectomy
Other illness
- Diabetes mellitus type I
Age
- Pregnancy (pregnancy test will be taken in women of reproductive age)
Who the study is looking for
- Age-related cataract
- Diabetes mellitus type II
- Metformin treatment
- Age 21 or older
- Written informed consent prior to surgery
Age in the registry: 21 years to 105 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vienna Institute for Research in Ocular Surgery (VIROS) Coordinator of this site? Confirm its status | Vienna | Austria | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.